MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice

MCC950, a Selective NLRP3 Inhibitor, Attenuates Adverse Cardiac Remodeling Following Heart Failure Through Improving the Cardiometabolic Dysfunction in Obese Mice

Obesity is often accompanied by hypertension. Although a large number of studies have confirmed that NLRP3 inhibitors can improve cardiac remodeling in mice with a normal diet, it is still unclear whether NLRP3 inhibitors can improve heart failure (HF) induced by pressure overload in obese mice. The...

Full description

Bibliographic Details
Main Authors: Menglong Wang, Mengmeng Zhao, Junping Yu, Yao Xu, Jishou Zhang, Jianfang Liu, Zihui Zheng, Jing Ye, Zhen Wang, Di Ye, Yongqi Feng, Shuwan Xu, Wei Pan, Cheng Wei, Jun Wan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
metabolic remodeling
MCC950
inflammasome
pressure overload
cardiac hypertrophy
heart failure
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.727474/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.727474/full

Similar Items